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Simple Summary: Targeting oncogenic protein tyrosine phosphatases (PTPs) with specific pharmacological
approaches has been considered for a long time a hard challenge, earning these PTPs the reputation
of “undruggable” enzymes. Nevertheless, PTPs have been recognized as main targets for several
diseases, including cancer, and great efforts have been made to identify novel PTPs inhibitors to fight
cancer progression and metastasis formation. Here, we summarize recent evidence underlining the
efficacy of this strategy for melanoma treatment. In particular, we illustrate how this approach could
be applied to target both cancer cells and the immune infiltrate of tumors, providing a new promising
adjuvant therapy for the treatment of melanoma.
Abstract: Despite a large number of therapeutic options available, malignant melanoma remains
a highly fatal disease, especially in its metastatic forms. The oncogenic role of protein tyrosine
phosphatases (PTPs) is becoming increasingly clear, paving the way for novel antitumor treatments
based on their inhibition. In this review, we present the oncogenic PTPs contributing to melanoma
progression and we provide, where available, a description of new inhibitory strategies designed
against these enzymes and possibly useful in melanoma treatment. Considering the relevance of
the immune infiltrate in supporting melanoma progression, we also focus on the role of PTPs in
modulating immune cell activity, identifying interesting therapeutic options that may support the
currently applied immunomodulating approaches. Collectively, this information highlights the value
of going further in the development of new strategies targeting oncogenic PTPs to improve the
efficacy of melanoma treatment.
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1. Introduction
Reversible tyrosine phosphorylation is one of the most important post-translational modifications,
which regulates key aspects of cellular biology, such as protein stability, protein–protein interactions,
and enzyme activity [1], thereby modulating the functionality of fundamental elements involved in
signaling transduction of mammalian cells [2]. The intracellular tyrosine phosphorylation level is
maintained by a strict balance between the activities of protein tyrosine kinases (PTKs) and protein
tyrosine phosphatases (PTPs), which catalyze respectively the addition or the removal of phosphate
from tyrosyl residues of their substrates [3]. An imbalance in this regulation is a well-recognized
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feature of several diseases, including cancer, since it induces alterations in cell growth and survival,
cell migration, and tissue differentiation [4,5]. While the role of PTKs as oncogenic proteins has been
largely described, allowing the development of a wide range of inhibitors already accepted in clinical
use [6,7], an effective strategy to modulate PTPs for cancer therapy has yet to be identified [8].
PTPs are a large family of proteins consisting of 107 members that can be classified into four
families (class I, II, III, and IV) according to the amino acid sequence at the catalytic domains [9].
Originally, PTPs were described to exclusively have a role as tumor suppressors, counteracting the
activity of PTKs. However, further studies brought to light that some PTPs can also function as
oncogenes depending on the availability of their functional partners and tumor type [5]. Such flexibility
in functions can be explained considering that, differently from PTKs, PTPs can act both as negative
and positive regulators of signal transduction pathways and can either activate or inhibit the oncogenic
role of PTKs. Indeed, PTPs can exert their function by directly dephosphorylating PTKs, or, indirectly,
by interfering with their downstream targets [10].
Starting from these bases, a deeper understanding of the dual role of PTPs in affecting tumor
progression could lead to the development of new therapeutic strategies aimed at targeting different
classes of tumors [11].
Despite the increasing evidence demonstrating the contribution of oncogenic PTPs in supporting
tumor progression, the number of inhibitors available to date is still extremely limited. Primarily,
this is due to the fact that PTPs have been considered for a long time as “undruggable targets”,
delaying the design of pharmacological inhibitors [12–14]. In particular, the nature of PTP active sites
represents a big challenge for the development of specific inhibitors active inside the cells [14,15].
First of all, in order to target the highly positively charged PTP active site, it would be necessary to
develop negatively charged molecules, a characteristic that unfortunately strongly limits their cell
permeability and bioavailability. However, promising prospects have come from the recent discovery
of nonhydrolyzable, polar, and cell-permeable pTyr mimetics that gave a new chance to overcome
these problems [12]. Moreover, designing specific PTP inhibitors is further complicated by the excellent
conservation of the amino acid sequence inside the active site among PTPs [13]. Remarkably, although
crystal structures of different members of the class-I PTPs revealed a common Cα-backbone signature,
the surfaces around the PTPs’ catalytic site are characterized by distinct properties, including different
topology, electrostatic potential, and lipophilic features, that can be addressed when designing novel
selective inhibitors [16–19]. Furthermore, the identification of allosteric inhibitors is crucial to avoid
targeting of the charged and conserved PTP active site, allowing the development of cell-permeable
and selective compounds [20–22]. Another central obstacle is the presence of a shallow pocket at the
PTPs’ catalytic site. This issue could be solved by proposing bidentate inhibitors, targeting both the
active site and proximal non-conserved binding sites that are present in most of the PTPs [23,24].
Finally, another major challenge that has emerged during the screening of PTP inhibitors is the
susceptibility of these enzymes to radical oxygen species (ROS), a phenomenon that in the past has
often led to erroneous conclusions during investigations about possible inhibitors. Indeed, it is known
that several anticancer drugs increase ROS production through redox cycling or the inhibition of ROS
scavenger enzymes [25]. In analogy to other cysteine-based enzymes, the activity of PTPs is highly
susceptible to oxidation of catalytic cysteine residues, which leads to the complete inactivation of these
enzymes [26]. This evidence highlighted that, in order to avoid an erroneous interpretation of the
mechanism of action of PTP inhibitors, their ability to generate ROS should always be evaluated both
in vitro and in vivo. As far as this topic is concerned, the studies conducted in the past to analyze the
mechanism of action of different types of cysteine protease inhibitors could be kept in mind as pivotal
examples [27–29].
Noteworthy, some of the PTPs recognized to have oncogenic properties have been found to be
overexpressed in highly metastatic melanoma [30–35], providing the opportunity to develop new
strategies to fight this disease.
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Malignant melanoma is an aggressive form of cutaneous neoplasia that derives from a series of
alterations occurring in melanocytes, the melanin-producing cells resident in the basal layer of the
epidermidis [36]. Melanoma retains the highest mortality rate among skin cancers and the highest
potential of dissemination [37]. The majority of melanoma patients develop the cutaneous form of
the disease, while non-cutaneous melanomas (which include tumors of the ocular and mucosal sites,
such as anorectal, vaginal, nasal, and gastrointestinal tract) are relatively rare [38]. Both classes of
melanoma are considered as a multi-factorial disease, whose pathogenesis is affected by environmental
and genetic factors. However, the differential incidence of genetic alterations among melanoma
subtypes and the unequal exposure to UV radiation, according to the anatomic site, strongly influence
the molecular pathways involved in tumorigenesis, ultimately leading to the need for specific therapies
against the different subtypes [39].
Data published in the Cancer Genome Atlas (TCGA) Network classify cutaneous melanomas
into four genetic subgroups on the basis of the most frequently mutated genes involved in the
mitogen-activated protein kinase (MAPK) pathway: BRAF, RAS (N-H-K), NF1, and triple wild-type
(WT) melanomas [40,41]. Mutations in BRAF and NRAS are most commonly detected in primary
cutaneous melanomas [42]. In particular, BRAF is mutated in about 50% of cutaneous melanomas,
and among these, in 80–90% of the cases, the missense activating mutation V600E is present. Besides,
NRAS mutations occur in about 20–25% of melanomas [43,44]. Following BRAF and NRAS, NF1 is
the third gene most commonly mutated in cutaneous melanoma (in about 17% of the cases) and
frequently co-occurs with mutations in the RASA2 gene [41,45,46]. NF1 mostly displays point
mutations, which determine a loss of function with consequent constitutive activation of the MAPK
and phosphoinositide 3-kinase (PI3K) pathways [47]. Interestingly, all these mutations finally result
in a constitutive activation of MAPK/ERK signaling, which indeed is present in 98% of melanomas,
promoting cellular proliferation, survival, and angiogenesis [48,49]. Finally, the loss of function of
PTEN is observed in about 10–35% of cutaneous melanomas, where it confers resistance to BRAF
inhibitors. This mutation results in a constitutive activation of the PI3K/AKT pathways, which, in turn,
leads to cell growth and proliferation and to the inhibition of apoptosis [50].
Conversely, non-cutaneous melanomas have significantly lower numbers of mutations: Acral
melanomas have, in about 15–20% of the cases, mutations in BRAF, NRAS, and KIT [51]; mucosal
melanomas display KIT mutations in about 15% of the cases (primarily in genitourinary or anal forms)
but rarely present mutations in BRAF and NRAS [52]; and uveal melanomas have distinct genomic
patterns, presenting mutations either in GNAQ or GNA11 in > 90% of the cases while BAP1, SF3B1,
and EIFAX are distinct subsets [53–55].
The involvement of protumoral PTPs in the oncogenic signaling pathways that characterize malignant
melanoma may pave the way for new possible combination therapies based on pharmacological inhibition
of oncogenic PTPs. Indeed, this approach could provide longer lasting therapeutic benefits through
the inhibition of multiple nodes in the main oncogenic signaling pathways. In agreement with
this hypothesis, Prahallad and co-authors found that the suppression of Src homology region 2
domain-containing phosphatase-2 (SHP-2) in BRAF mutant and in Vemurafenib-sensitive melanoma
cells inhibits growth factor-induced drug resistance and delays the onset of spontaneous resistance [56].
Moreover, they identified the activating phosphorylation site on Tyr542 of SHP-2 as a valid biomarker to
recognize patients with melanoma who have acquired Vemurafenib resistance due to receptor tyrosine
kinases (RTKs) activation [56]. Moreover, due to the central role of SHP-2 in mutant KRAS-driven
carcinogenesis, it has been demonstrated that the synergic inhibition of SHP-2 and MAPK/ERK kinase
(MEK) results in decreased tumor growth in xenograft models of pancreatic ductal adenocarcinoma
and non-small cell lung cancer, sustaining the utility of the dual SHP-2/MEK inhibition in KRAS
mutant cancers [57].
The overall survival of patients diagnosed with advanced melanoma has strongly increased over
recent years, thanks to the latest development of therapeutic strategies [58]. However, recurrence
frequently occurs due to therapy failure leading to metastasis formation, representing the main cause of
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patient death [59]. For this reason, many efforts have been made to design new therapeutic approaches
aimed at targeting the most aggressive stages of melanoma [60].
The data presented above underline that even if the PTP inhibitors available to date show only a
mild effect on cell proliferation, future efforts could be made to use these compounds in combination
with other pathway-targeted drugs to fight melanoma progression.
In this review, we will present a detailed overview of PTPs reported, up to date, to function as
oncogenes in melanoma, either facilitating tumor progression or dampening the immune response.
This information lays the foundation for the design of new therapeutic strategies specifically directed
against oncogenic PTPs in melanoma [61].
2. Oncogenic Protein Tyrosine Phosphatases in Melanoma
Among the 107 known PTPs, several of them have been identified to have an oncogenic role in
different types of cancers [10]. Interestingly, recent evidence highlights their importance in supporting
melanoma progression, as discussed in the following sections.
2.1. Cell Division Cycle 25 Proteins (CDC25s)
CDC25s are a family of dual-specificity phosphatases (DSPs), known to act as key regulators
of cell cycle progression and DNA damage handling, through the activation of cyclin-dependent
kinase (CDK) complexes. CDC25s remove inhibitory phosphates from both threonine and tyrosine
residues present on the phosphate-binding loop of CDKs [62]. Their inactivation or degradation leads
to cell cycle arrest [63,64]. Hence, it is not surprising that CDC25 deregulation may lead to genomic
instability and cancer transformation [64]. In humans, there are three distinct CDC25 genes (CDC25A,
B, and C), which specifically dephosphorylate and activate various targets [63]. All the three isoforms
are involved in tumorigenesis, even if with varying extent. Specifically, the overexpression of either
CDC25A and/or CDC25B has been observed in multiple tumor types, including melanoma, where it
is frequently associated with a more aggressive and metastatic phenotype [32,62,65–67]. By contrast,
the role of CDC25C seems to be less important for tumorigenesis [68–70]. Interestingly, Kaplan–Meier
curves of melanoma patients confirm the correlation between the higher expression of all the three
isoforms and a worse clinical outcome [71–74].
Considering the importance of CDC25s in facilitating cell cycle progression and cell proliferation,
these proteins are potentially very interesting targets for melanoma treatment. Determination of the
crystal structures of the catalytic domain of CDC25A (PDB: 1C25) [75] and CDC25B (PDB: 1QB0) [76],
alongside recent progression in bioinformatic approaches, facilitated the identification of numerous
compounds with inhibitory effects on these enzymes [61].
In particular, as far as melanoma is concerned, triptolide (TPL), a diterpene triepoxide natural
compound, has been demonstrated to be active in different cancers and, specifically, on the A375.S2
melanoma cell line. Treatment with this compound induces cyclin A and CDC25A inhibition, thereby
causing arrest of the cell cycle in S phase. In addition, the exposure of A375.S2 melanoma cells to TPL
leads to apoptosis through caspase-8, -9, and -3 activation [77]. Moreover, cantharidin (CTD), another
natural compound that shares many characteristics with TPL, shows a similar ability to inhibit cyclin
A and CDC25A in the A375.S2 melanoma cell line [78].
Noteworthy, Capasso and co-workers, using both experimental and bioinformatic methods,
developed several quinonoid derivatives, acting as CDC25 irreversible inhibitors [63]. The mechanism
of action of these compounds involves electrophilic modification or ROS-induced oxidation [79,80]
of the catalytic cysteine residue in the PTP active site [81,82]. Among the molecules selected with
this strategy, nine were identified with Ki values in the range of micro- and nano-molar and one of
them (referred to as “compound 7”) showed efficacy on melanoma cells (A2058 and SAN), arresting
their proliferation in G2/M phase and inducing a strong antiproliferative effect [63]. In the same paper,
the authors also assessed that treatment with compound 7 stimulates the intrinsic apoptosis pathway
in a caspase-dependent manner and leads to a reduction of the CDC25C protein level (and, at a
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lower extent, of CDC25A) [63]. However, the mechanism of action of these quinonoid-based agents
may cause many different unrelated events, due to ROS reaction with other phosphatases and with
unrelated enzymes. These possibilities represent a serious limit to their therapeutic applications, due to
the potential toxicity.
In order to circumvent this issue, more recently, Cerchia and co-authors performed a screening of
different classes of molecules, starting from the lead inhibitor NSC28620. This approach allowed them
to identify naphthylphenylketone and naphthylphenylamine derivatives, acting as CDC25 inhibitors
in two aggressive human melanoma cell lines, namely A2058 and A375. In contrast with quinonoid
derivatives, these compounds reversibly inhibit the enzymes (in particular, the CDC25B isoform)
without generating ROS. Altogether, these characteristics make these inhibitors more interesting
for possible anticancer therapy. In agreement, the reported results indicate that the treatment with
these compounds affects cell cycle progression, with increased G2/M phase and reduced G0/G1
phase accumulation, by causing an increase in the phosphorylated form of cyclin-dependent kinase 1
(CDK1) [83] (Figure 1).
Figure 1. Effects of Cell Division Cycle 25 Proteins (CDC25s) targeting on melanoma cells. CDC25
phosphatases act as key regulators of the cell cycle, dephosphorylating cyclin-dependent kinases
(CDK1, CDK2, CDK4, and CDK6) and cyclins (cyclin D, B, A, and E complexes). Several quinonoid
derivatives, naphthylphenylketones and naphthylphenylamine derivatives, act as CDC25 inhibitors,
arrest cells in the G0/G1 and G2/M phases of the cell cycle, and significantly inhibit the proliferation
and colony formation ability of melanoma cells.
It should be underlined that the inhibitors so far cited are not closely specific for CDC25s and the
question on their toxicity still remains open. Indeed, all the presented experiments, although showing
clear cut results, are limited to in vitro melanoma models. More efforts are needed to confirm the
efficacy of these new compounds as tools for melanoma treatment.
2.2. Low-Molecular-Weight Protein Tyrosine Phosphatase (LMW-PTP)
LMW-PTP belongs to the non-transmembrane PTPs sub-family and consists of 157 amino acids [84].
Two isoforms, generated by alternative splicing of a single gene and characterized by different activities
and substrate specificities, have been found in mammalian cells [85].
Previous studies revealed that this enzyme displays a wide number of substrates, including the
platelet derived growth factor (PDGF) receptor [86], insulin receptor [87], Ephrin A2 (EphA2) [88,89],
and several non-receptor proteins, such as proto-oncogene tyrosine-protein kinase Src (Src) [90],
focal adhesion kinase (FAK) [91], caveolin [92], signal transducer and activator of transcription 5
(STAT5) [93], β-catenin [94], and p190RhoGAP [95], thereby modulating key signaling pathways
involved in tumor growth, differentiation, migration, and invasion [85,89]. In this context, it is not
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surprising that LMW-PTP has been found to be overexpressed in several types of human [96] and rat
tumors [97], where it promotes an aggressive and malignant phenotype [98–100].
Recently, it has been demonstrated that LMW-PTP is overexpressed in melanoma cells, contributing
to the regulation of cancer cell sensitivity toward chemo- and radiotherapy. Interestingly, it has been
highlighted that the treatment of melanoma cells with morin, a non-toxic natural LMW-PTP inhibitor,
is able to increase the sensitivity of tumor cells toward both dacarbazine and radiotherapy [31].
Coherently, data reported in The Human Protein Atlas database show that in melanoma patients,
unfavorable prognosis is associated with high LMW-PTP expression levels, thereby confirming the
role of this enzyme in regulating the in vivo survival and proliferation rate of melanoma cells [71,101].
Collectively, these findings suggest that LMW-PTP could be an interesting target to improve the
effectiveness of anticancer treatment for melanoma patients that are naturally refractory to the therapies.
2.3. FAS-Associated Phosphatase 1 (FAP-1)
FAP-1 (or PTPN13/PTP-BAS) is a protein tyrosine phosphatase that interacts with the cytosolic
portion of the Fas cell surface death receptor (FAS), whose activation leads to cell apoptosis.
FAP-1 interaction negatively regulates FAS-initiated apoptosis, preventing FAS export from the
cytoplasm to the cell surface [102]. Other reported FAP-1 binding partners include the nuclear factor of
kappa light polypeptide gene enhancer in B-cells inhibitor, α (IκBα), the Rho GTPase activated protein
1 (RhoGAP1), Ephrin B1, and the transient receptor potential cation channel M2 (TRPM2). In particular,
IκBα is a putative FAP-1 substrate, being the only FAP-1-binding protein that is also dephosphorylated
by this phosphatase [103].
Since FAP-1 negatively regulates FAS-initiated cell apoptosis, it has been suggested to positively
affect tumor progression. Accordingly, FAP-1 has been reported to inhibit FAS-mediated apoptosis
in pancreatic adenocarcinoma [104,105] and melanoma [106]. Interestingly, human melanoma cells
silenced for FAP-1 show increased surface FAS expression and respond to recombinant FAS ligand
(FasL) treatment by the induction of apoptosis [106]. Contrary to the possibility of blocking FAP-1 for
the treatment of melanoma, there is also evidence that FAP-1 can act as a tumor suppressor in some
cancer types. For example, reduced PTPN13 mRNA expression due to promoter hypermethylation
or allelic loss has been observed in gastric and hepatocellular carcinomas [107,108]. Such a diversity
of functions described for FAP-1, with positive and negative roles in a context-dependent manner,
could be explained considering that it is among the largest intracellular PTPs, containing eight
domains [109]. Despite the demonstrated role of this PTP in melanoma, to date, at least to our
knowledge, no therapeutic approaches have been developed to inhibit FAP-1 in this tumor type,
leaving open the possibility of designing new inhibitors.
2.4. Mitogen-Activated Protein Kinase Phosphatase-1 (MKP1)
MKP1 is a member of the threonine-tyrosine dual-specificity phosphatase family. MKP1 targets
different members of the MAPK family that regulate cell proliferation and apoptosis, including
extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38 MAPK [110].
Different evidence demonstrates that MKP1-mediated JNK dephosphorylation/inactivation is essential
to protect tumor cells from anticancer drug-induced apoptosis [111,112]. Interestingly, melanoma
patient survival analyzed by the Kaplan–Meier curve describes a correlation between high levels of
MKP1 and poor prognosis [71,113]. Therefore, the inhibition of MKP1 may be an effective strategy to
enhance the activity of antitumor therapy [114,115]. Promising results in this context come from a study
by Kundu and co-workers, who demonstrated that by combining the interferon-α2b (IFN-α2b) with a
new selective MKP1 inhibitor, tyrosine phosphatase inhibitor-3 (TPI-3), it is possible to obtain better
results than those achieved with IFN-α2b or TPI-3 alone in inhibiting melanoma growth both in vitro
and in a xenograft nude mice model. Interestingly, the authors reported that TPI-3 is a well-tolerated
compound and that mice treated with TPI-3 alone did not experience loss of weight, abnormalities in
behaviors, or anatomic alterations [116] (Figure 2). All together, these findings suggest that therapeutic
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strategies based on the treatment with MKP1 inhibitors could contribute to improve the prognosis of
patients affected by tumors expressing high MKP1 levels, such as melanoma.
Figure 2. Effect of Mitogen-Activated Protein Kinase Phosphatase-1 (MKP1) targeting on melanoma
cells. Overexpression of MKP1 phosphatase in melanoma cells contributes to enhance resistance toward
anticancer drugs. For this reason, MKP1 inhibition is sufficient to enhance cancer cell death in culture
and to sensitize cancer cells towards cytotoxic drugs. Among the substrates of MKP1, there is JNK.
MKP1 dephosphorylates JNK, inhibiting its activation, and thereby avoiding apoptosis.
2.5. Phosphatase of Regenerating Liver (PRL)
The family of PRL consists of three members, namely PRL1, PRL2, and PRL3, and is a unique
class of oncogenic dual-specificity phosphatases (alternatively known as protein tyrosine phosphatase
4A, PTP4A). Kaplan–Meier curve analysis of patients affected with melanoma shows a clear correlation
between PRL phosphatase expression and poor survival [71,117,118].
Despite their role in cancer being well documented, the molecular functions of these proteins
are still not completely understood [119]. PRL3 modulates different signaling pathways involving
p53, MAPK, protein kinase B (PKB, also known as AKT), mammalian target of rapamycin (mTOR),
signal transducer and activator of transcription 3 (STAT3), FAK, and vascular endothelial growth factor
(VEGF), hence positively acting on tumor cell proliferation and aggressiveness [120]. PRL3 is also
able to dephosphorylate the PI (4,5) P2 phosphoinositide, thereby contributing to modulation of the
tumoral phenotype [121].
In addition, PRL3 promotes cell motility, invasion, and metastasis formation through different
mechanisms, including its mutual activation involving the kinase Src [122], the accumulation of
MMO14 matrix metalloprotease [123], and the downregulation of the tumor suppressor phosphatase
and tensin homolog (PTEN), with consequent epithelial–mesenchymal transition [124]. Interestingly,
in a very recent paper, PRL2 overexpression was also correlated with PTEN downregulation and
poor patient survival. In particular, the authors proved that PRL2 directly downregulates PTEN by
dephosphorylating its Tyr336 residue, thus increasing PTEN ubiquitination and degradation [125].
Overexpression of PRL3 has been demonstrated in many different solid tumors, including
metastatic melanoma [30]. This finding was further confirmed by Wu and colleagues, who demonstrated
a higher expression of PRL3 in the metastatic melanoma cell line B16-BL6 with respect to its
less metastatic counterpart B16 cells, highlighting a clear role of PRL3 in promoting metastasis
formation [126]. Daouti and co-authors established that while ectopic PRL3 overexpression induces
cell transformation and increases motility and invasiveness, PRL3 silencing prevents anchorage-
independent cell growth in soft agar [30]. The authors suggested that the adaptor protein p130Crk-
associated substrate (p130Cas) is involved in this mechanism. Specifically, they demonstrated that
treatment with thienopyridone, a selective inhibitor of all the three PRL isoforms, induces p130Cas and
FAK cleavage, leading to the induction of caspase-mediated cell apoptosis and cancer cell anoikis [30].
Coherently, it was also shown that siRNA-mediated PRL3 depletion is able to inhibit the metastatic
potential of B16-BL6 mouse melanoma cells both in vitro and in vivo [127].
Even if it has been known for a long time that a correlation exists between high PRL3 expression
and metastatic risk in patients with uveal melanoma [128], only recently has a specific role for PRLs
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been recognized in this aggressive and metastatic tumor. In particular, collapsin response mediator
protein 2 (CRMP2), a protein affecting microtubule dynamics, protein endocytosis, and vesicle recycling,
has been described as a new target for PRL3 phosphatase activity. Specifically, PRL3 dephosphorylates
CRMP2 on Thr514, thus enhancing cell invasiveness [129].
Considering the key role of PRL3 in mediating melanoma cell motility and metastasis formation,
several attempts have been performed in order to select specific PRL3 inhibitors [119]. Pathak and
colleagues identified pentamidine [1,5-di(4-amidinophenoxy)pentane] as a relatively specific inhibitor
of PRLs and tested its activity on several cancer cell lines, including the WM9 melanoma-derived cell
line. Interestingly, pentamidine was also tested in nude mice, where it was able to induce marked
tumor cell necrosis in engrafted WM9 human melanoma cells, without any obvious side effects [130].
In addition, the previously mentioned thienopyridone is another promising inhibitor of PRLs that has
been demonstrated to be effective in reducing the aggressiveness of melanoma cells by affecting their
metastatic potential [30] (Figure 3).
Figure 3. Effects of Phosphatase of Regenerating Liver-3 (PRL-3) targeting on melanoma progression.
Elevated PRL-3 leads to Src activation through the downregulation of the synthesis of C-terminal
Src kinase protein, which in turn leads to tyrosine phosphorylation of several proteins, including
STAT3, FAK, and p130Cas. Thienopyridone and pentamidine derivatives, which act as PRL3 inhibitors,
are effective in inhibiting melanoma cell proliferation, survival, and migration.
A possible alternative approach is based on the targeting of PRL1 trimer formation, a mechanism
necessary for PRL1-mediated cell proliferation and migration [131]. Using a computer-based virtual
screening, different specific compounds were selected as PRL1 trimerization inhibitors. Interestingly,
one of these compounds, referred to as “Cmpd-43”, displayed a strong anticancer activity both in vitro
and in vivo in a murine xenograft model of melanoma [132].
Even if further efforts are needed to improve both the effectiveness of the inhibitors described and
to reduce their side effects, the reported results suggest that PRLs could be an optimal target to reduce
melanoma aggressiveness.
An event that should be considered when developing new treatments targeting PRLs is its
interaction with the CNNM complexes (cyclin-M family, also termed cyclin and cystathionineβ-synthase
(CBS) domain magnesium transport mediators). This interaction is a key node in the regulation of
magnesium homeostasis [133], and cells that overexpress PRLs in complex with CNNMs accumulate
intracellular magnesium [134], which favors tumor proliferation and migration [135].
A possible more promising approach has very recently been developed using a humanized
antibody (PRL3-zumab) that is able to target externalized PRL3 protein on different human liver and
gastric tumor cell lines, used in an orthotopic tumor model in nude mice [136]. This antibody is currently
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under investigation in a phase 1 clinical trial on a wide range of solid tumors and hematological
malignancies (Trial Number: NCT03191682; Table 1).
Table 1. Protein tyrosine phosphatase (PTP) inhibitors involved in clinical trials for melanoma treatment.

















melanoma Phase I completed
NCT00498979 Sodiumstibogluconate SHP-1
Malignant
melanoma Phase I completed
PRL3: Phosphatase of Regenerating Liver-3; SHP-2: Src Homology Region 2 Domain-Containing Phosphatase-2;
SHP-1: Src Homology Region 2 Domain-Containing Phosphatase-1.
2.6. Src Homology Region 2 Domain-Containing Phosphatase-2 (SHP-2)
SHP-2, also termed tyrosine-protein phosphatase non-receptor type 11, is encoded by the PTPN11
gene [137]. SHP-2 contains two tandem SH2 domains, which act as phospho-tyrosine-binding
domains and mediate the interaction of the tyrosine phosphatase with its substrates [137]. SHP-2 is
auto-inhibited in the resting state, since the N-terminal SH2 domain binds to the catalytic cleft of the
PTP domain, thereby blocking the access of SHP-2 substrates to the active site. Upon binding to target
phospho-tyrosine residues, the N-terminal SH2 domain is released from the PTP domain and thus the
enzyme is catalytically activated by reverting its auto-inhibited conformation [138].
SHP-2 is ubiquitously expressed and plays a key role in different cell signaling events, such as
mitogenic activation, metabolic control, transcriptional regulation, and cell migration [139].
SHP-2 is the first tyrosine phosphatase identified as an oncogene in juvenile myelomonocytic
leukemia, myelodysplastic syndromes, and acute myeloid leukemia [140]. It is remarkable that the
gain-of-function mutations in SHP-2, leading to hyper-activated/deregulated mutants of the enzyme,
occur in about 50% of Noonan syndrome patients [141]. Importantly, increased SHP-2 expression is a
prognostic and a predictive marker of several malignancies and plays a key role in melanoma [142–149].
Indeed, this PTP has been found to be overexpressed and mutated in samples derived from melanoma
patients, correlating with a strong metastatic phenotype and a poorer prognosis [33–35]. These findings
were further confirmed by the Kaplan–Meier curve analysis, which revealed a strong correlation
between higher expression levels of SHP-2 and poor overall survival in melanoma patients [71,150].
Due to the involvement of SHP-2 in multiple growth factor-mediated oncogenic pathways,
such as the Ras/ERK1/2 pathway, and to its fundamental role in several tumors, inhibition of SHP-2
is considered to have broad therapeutic applications in the treatment of various cancers, including
melanoma [151].
The PTP inhibitor sodium stibogluconate (SSG), a drug used in the treatment of leishmaniasis [152]
and identified as an inhibitor of both SHP-1 and SHP-2 [153], increases interferon-α (IFN-α)-induced
signal transducer and activator of transcription 1 (STAT1) tyrosine phosphorylation and has been
shown to synergize with IFN-α to inhibit WM9 human melanoma tumor growth in nude mice [154].
Accordingly, Win-Piazza and co-workers demonstrated that suppression of SHP-2 increases the antitumor
activity of IFN-α2b in A375 melanoma tumor xenografts. Indeed, IFN-α2b exerts antiproliferative
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effects on A375 cells through STAT1/STAT2 tyrosine phosphorylation, which is negatively regulated
by SHP-2. In keeping with these data, treatment with the SHP-2 inhibitor, SPI-112, increases the
IFN-α2b-stimulated STAT1 phosphorylation and inhibits A375 cell growth [155].
Furthermore, Soong and colleagues revealed a peculiar role of SHP-2 in melanocytes. Specifically,
Plexin B1 and tyrosine protein kinase Met (MET) assemble in an oligomeric receptor-receptor complex in
melanocytes and Semaphorin-4D (Sema4D) increases this association. The consequent MET activation
correlates with the transformation of melanocytes to melanoma [156]. SHP-2 mediates, at least in
part, the effects downstream to the MET receptor, and this phosphatase is required for the activation
of the MAPK and AKT signaling pathways in response to hepatocyte growth factor (HGF) [157,158].
The blockade of SHP-2 phosphatase activity with the inhibitor NSC-87877 reduces HGF-induced MET
activation and subsequently ERK1/ERK2 and AKT phosphorylation, suggesting an important role
for SHP-2 in transducing proliferative and prosurvival signals in melanocytes [156]. Consequently,
inhibition of SHP-2 can be proposed as a novel target to halt the transformation of melanocytes
in melanoma.
Furthermore, SHP-2 acts as an oncogene in BRAF wild-type (either NRAS mutant or wild-type)
melanoma cells. Indeed, both silencing of the activated SHP-2 E76K mutant or the administration
of the allosteric SHP-2 inhibitor, SHP099, causes regression of the established melanoma, thereby
suggesting that SHP-2 could be considered as a therapeutic target for BRAF wild-type melanoma [34].
It is widely described that HGF confers resistance to the BRAF inhibitor Vemurafenib in BRAF-
mutant melanoma cells [159]. Interestingly, recent evidence underlines that SHP-2 is necessary to
mediate this mechanism of resistance. Indeed, Prahallad and co-workers revealed that SHP-2 knockout
clones of SK-Mel888 BRAF(V600E) mutant melanoma cells were unable to confer Vemurafenib
resistance, following HGF, fibroblast growth factor 9 (FGF9), and stem cell factor (SCF) exposure [56].
Furthermore, it has been demonstrated that SHP-2 also drives adaptive resistance to RAS viral (v-raf)
oncogene homolog (RAF) and MEK inhibitors in other tumor types [160]. Accordingly, Ahmed and
co-authors proved that co-targeting of MEK and SHP-2 could serve as a powerful therapeutic approach
in triple-negative breast cancer and showed that SHP-2 inhibition impairs adaptive resistance to
Vemurafenib in a subset of BRAF(V600E) colorectal and thyroid cancers. These results suggest that
SHP-2 blockade successfully overcomes adaptive resistance to BRAF and MEK inhibitors in a defined
subgroup of ERK-dependent tumors, keeping the possibility open for exploiting this strategy for
melanoma treatment.
Moreover, SHP-2 acts as a scaffold protein recruiting growth factor receptor-bound protein 2/Son of
Sevenless (GRB2/SOS) complex to the membrane and promoting RTK-mediated RAS activation [161,162].
It is noteworthy that the allosteric SHP-2 inhibitor SHP099 stabilizes the phosphatase in its inactive
conformation [22], thus preventing the assembly of SHP-2 with other adaptor proteins to achieve the
complete activation of RTK signaling. In keeping with this, Zhang and colleagues demonstrated that
SHP-2 overexpression enhances melanoma MeWo cell viability, motility, and anchorage-independent
growth, through positive regulation of the ERK1/2 and PI3K/AKT pathway [35]. Accordingly, SHP-2
knockdown is able to revert these effects. Indeed, the specific SHP-2 inhibitor 11a-1 [163], an indole
salicylic acid inhibitor, reduces the aforementioned phenomena in melanoma cells by downregulating
the SHP-2-mediated ERK1/2 and AKT signaling pathways. Moreover, in vivo experiments demonstrated
that 11a-1 significantly reduces xenografted melanoma tumor growth (Figure 4).
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Figure 4. Effects of Src Homology Region 2 Domain-Containing Phosphatase-2 (SHP-2) targeting on
melanoma cells. Left: SHP-2 has a key role in promoting the proliferation and survival of melanoma cells.
SHP-2 dephosphorylates RasGAP, an inhibitor of Ras. Therefore, SHP-2, by activating Ras, promotes the
RAS/RAF/ERK1/2 pathway, which sustains melanoma cell proliferation. Right: SHP-2 dephosphorylates
GRB2-associated-binding protein 1 (GAB1), which releases PI3K, promoting activation of the PI3K/AKT
pathway, melanoma cell growth, and survival. NSC-87877 and SHP099 inhibit SHP-2, impairing
melanoma cell proliferation. SHP-2 also has an important role in regulating signaling activated by
IFN-α2b. SHP-2 dephosphorylates STAT1, hindering its dimerization and its migration into the
nucleus, where it stimulates the transcription of several genes, resulting in melanoma cell growth arrest.
Overexpression of SHP-2 in melanoma cells blunts the response to IFN-α, favoring melanoma cell
survival and dissemination. SSG, SPI-112, and TPI-1a4 are potent inhibitors of SHP-2, enhancing the
anti-proliferative activity of IFN-α.
Overall, following the clear correlation between high expression levels of SHP2 and poorer
survival of melanoma patients, several findings strongly suggest that SHP-2 may act as a targetable
substrate against melanoma. In this perspective, SHP-2 inhibitors can be proposed as novel therapeutic
approaches for melanoma treatment [35].
In keeping, TNO155, a recently discovered orally bioavailable SHP-2 inhibitor with antitumor
activity in xenograft models [164], is currently in clinical trials for the treatment of solid tumors,
including melanoma (Trial Number: NCT03114319; Table 1).
3. Role of PTPs in Immune Melanoma Cell Infiltrate
Melanoma is reported as one of the most immunogenic tumors characterized by a crosstalk between
cancer cells and immune cells, which strongly affects cancer progression and metastasis [165]. Indeed,
during melanomagenesis, activated T cells are recruited to the melanoma microenvironment through a
“homing” mechanism, in order to recognize melanoma antigens and attack tumor cells, finally inducing
cell death by the apoptosis pathway or the granule exocytosis pathway [166,167]. Interestingly, patients
affected by melanoma with high CD8+ T cell infiltrate both in primary tumor and metastasis have better
outcomes [168]. Targeting of the host immune response in melanoma with immunotherapies is one of
the most interesting approaches used in the last decades to fight this malignancy [169]. Metastatic
melanoma is mainly treated with Food and Drug Administration (FDA)-approved immune checkpoint
inhibitors, such as Ipilimumab, Pembrolizumab, and Nivolumab [170–173]. However, many patients
fail to respond to immunotherapy and frequently develop primary or secondary resistance, highlighting
the need for supportive therapies to fight melanoma [174,175]. Several studies underlined that PTPs
can exert an important role in modulating the immune infiltrate, thereby affecting melanoma growth.
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Hence, inhibition of these PTPs might represent a novel strategy to be combined with the already
consolidated immunotherapies.
3.1. Src Homology Region 2 Domain-Containing Phosphatase-1 (SHP-1)
SHP-1, also known as protein tyrosine phosphatase non-receptor type 6 (PTPN6), encoded by the
PTPN6 gene, belongs to the family of non-receptor PTPs. This enzyme localizes to the cytosol and
it is primarily expressed in hematopoietic cells, whereas it is present only at low levels in epithelial
cells [176,177]. Similarly to SHP-2, SHP-1 is characterized by two tandem N-terminal SH2 domains that
regulate the enzyme activity. The three-dimensional crystal structure of ligand-free SHP-1 revealed
that this tyrosine phosphatase displays an auto-inhibited conformation [178].
SHP-1 was initially classified as a tumor suppressor phosphatase [179] since its silencing, due to
hypermethylation of CpG islands in the PTPN6 promoter region, is frequently associated with a
poor prognosis and worse outcome in different types of cancers [180–189]. Indeed, several studies
underlined that this enzyme controls cell cycle progression by impairing PDGF and insulin receptor
signaling [190,191]. Moreover, Nagakami and co-authors demonstrated that in endothelial cells,
SHP-1 activation by tumor necrosis factor-alpha (TNF-α) inhibits VEGF- and epidermal growth factor
(EGF)-mediated proliferation [192].
Despite the widely described tumor suppressor activity of SHP-1, recent studies demonstrated that
this phosphatase could also act as an oncogene [193,194]. In particular, growing evidence highlights
that SHP-1 is involved in modulation of the tumor microenvironment and impacts on immune
infiltrate activation.
Specifically, SHP-1 is a key negative regulator of cytokine signaling and immune cell activity [195,196].
This tyrosine phosphatase limits T cell responsiveness by directly targeting T cell receptor (TCR)
chain-ζ or downstream effectors, including the lymphocyte-specific protein tyrosine kinase (Lck),
the zeta-chain-associated protein kinase 70 (ZAP70), the proto-oncogene vav (Vav), and PI3K [176,197].
Recently, Watson and co-authors highlighted that SHP-1 deficiency increases the ability of adoptively
transferred CD8+T cells to impair tumor growth [198]. In addition, an enhanced in vivo cytotoxicity of
naive SHP-1-deficient T cells was observed, highlighting the validity of targeting SHP-1 expression to
boost human CD8+T cell functionality [199,200] (Figure 5).
Figure 5. Effects of Src Homology Region 2 Domain-Containing Phosphatase-1 (SHP-1) targeting in T
cells. Tumor-infiltrating lymphocytes express SHP-1, which regulates the TCR-driven T cell activation
threshold and inhibits early events after TCR triggering. The SHP-1 inhibition increases interaction
of CD8+ T-cells with antigen presenting cells (APCs), leading to reduced activation thresholds and
increased proliferation of antitumor T cells. Therefore, the inhibition of SHP-1 improves the ability of
immune cells to suppress melanoma cell growth.
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Considering the relevance of the immune infiltrate in supporting melanoma progression, targeting
SHP-1 with specific inhibitors could be a promising novel strategy to improve the efficacy of cytokine
therapy and immunotherapy, which are among the most successful approaches in clinical use for
melanoma treatment [201,202]. For this purpose, different SHP-1 inhibitors have been developed,
displaying antitumor potential in advanced cancer patients, including melanoma patients [153,203–205],
as demonstrated by two different clinical trials (Trial Number: NCT00629200 and NCT00498979; Table 1).
In this context, Yi and colleagues demonstrated that SSG inhibitor synergizes with IFN-α to overcome
IFN-α resistance in different human cancer cell lines and extinguishes IFN-α-refractory WM9 human
melanoma tumors in nude mice without displaying adverse effects [154].
More recently, a novel SHP-1 tyrosine phosphatase inhibitor-1 (TPI-1) was identified through the
screening of a library of 34,000 drug-like compounds. TPI-1 was more effective than SSG in SHP-1
inhibition, immune cell activation, and antitumor potential [205]. Furthermore, Kundu and co-workers
revealed that TPI-1 increases the expression of interferon-γ (IFN-γ), a cytokine produced during
the activation of antitumor cells, in vitro, in mouse splenocytes, and in human peripheral blood.
Interestingly, these authors also found that TPI-1 has anticancer potential on B16 melanoma thanks
to the described induction of IFN-γ and demonstrated that B16 tumor growth is inhibited following
TPI-1 treatment. Moreover, the antitumor activity of TPI-1a4, a TPI active analogue, was evaluated on
the UV-induced K1735 murine melanoma with promising results [205].
Furthermore, Ramachandran and co-workers described the central role of SHP-1 in dendritic cell
(DC) function. Indeed, this phosphatase inhibits numerous downstream effectors of multiple receptors,
such as the nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB), the activator protein
1 (AP-1), ERK, and JNK, as well as cytokine production in DCs. Accordingly, SSG-mediated inhibition
of SHP-1 promotes proinflammatory cytokine production and increases the survival and migration
of dendritic cells. Since DC signaling is required for the initiation of T cell immunity, SHP-1 is also
able to reduce the ability of DCs to induce antigen-specific T cell proliferation. Finally, these authors
assessed that SHP-1 inhibition in DCs could enhance their potency as antitumor vaccines. It is notable
that mice bearing B16F10 melanoma, vaccinated with SHP-1-silenced DCs or with SHP-1 dominant
negative DCs, showed a significantly slower tumor growth if compared to controls. Interestingly,
this result suggests that inhibition of SHP-1 in DCs can improve their efficacy as in vivo antitumor
vaccines against melanoma [206].
Moreover, a recent study demonstrated that SHP-1 inhibition in combination with immune
checkpoint blockade treatment (anti-PD1 and anti-CTLA4) increases the recruitment and the effectors’
function of low-affinity T cells, finally leading to melanoma tumor regression by increasing the
frequency of IFN-γ-producing endogenous antitumor CD8+T cells [207]. Collectively, this evidence
highlights the role of SHP-1 as an oncogene in the tumor microenvironment, specifically in the immune
cell population, suggesting that it may be a promising target to enlarge the repertoire of T cells sensitive
to checkpoint blockade, finally leading to enhanced control of melanoma growth.
Notably, new efforts are needed to modulate SHP-1 activity in the selected immune cell population,
which would be a significantly better strategy to impair tumor growth, rather than globally inhibit
SHP-1 activity, independently of the cell subset. This approach could be particularly suitable in
melanoma treatment, where immunotherapy is becoming increasingly important [208].
3.2. Src Homology Region 2 Domain-Containing Phosphatase-2 (SHP-2)
Recent evidence suggests a role of SHP-2 in tumor immunity. Specifically, following engagement
with its ligands, mainly PD-L1, programmed cell death protein 1 (PD-1) is activated and recruits
SHP-2 in the proximity of TCR and CD28. Consequently, SHP-2 dephosphorylates and decreases
TCR and CD28 pathways, leading to the inhibition of T cell proliferation and activation, ultimately
causing activated T cell death [209]. In keeping with this, Wu and co-workers recently showed that B16
melanoma cell-derived exosomes deliver SHP-2 to tumor-infiltrating lymphocytes, thus suppressing
their function and inhibiting their proliferation [210]. Moreover, it has been demonstrated that
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SHP-2 suppression in macrophages may promote a Th1-dominant tumor immune microenvironment,
which is advantageous to suppress melanoma growth. Indeed, the deletion of SHP-2 increases
macrophage production of chemokine (C-X-C motif) ligand 9 (CXCL9) in response to IFN-γ and tumor
cell-derived cytokines, promoting T cell infiltration into the tumor [211]. Other evidence highlighting
the importance of SHP-2 targeting in tumor-based immunotherapy comes from the studies of Ramesh
and co-workers [212]. These authors demonstrated that the treatment with dual-inhibitor-loaded
nanoparticles (DNTs), which simultaneously inhibit macrophage colony-stimulating factor 1 receptor
(CSF1R) and SHP-2 pathways, results in an efficient re-polarization of M2 macrophages to their active
M1 phenotype. Moreover, DNTs display antitumor activity without any toxicity in melanoma in
both in vitro and in vivo settings [212]. In conflict with previous evidence, Zhang and co-authors
highlighted that the expression of SHP-2 in CD4+ T cells exerts tumor-suppressing effects on melanoma.
Indeed, they demonstrated that SHP-2 deletion in CD4+ T cells potentiates melanoma progression and
promotes metastasis in mice [213] (Figure 6).
Figure 6. Targeting of SHP-2 in immune cells. After binding with PD-L1 ligand exposed by cancer
cells or APC cells, PD-1 undergoes activation and recruits SHP-2, which can dephosphorylate ZAP70
or activate CD28 immune receptor. By this mechanism, SHP-2 inhibits signaling originated by TCR
and CD28, thereby leading to a reduction in TCR-mediated interleukin-2 (IL-2) production and the
impairment of T cell proliferation. Conversely, the treatment with SHP-2 inhibitors, such as NSC-87877,
SHP099, and SSG, enhances lymphocyte activation and cytokine release, and stimulates lymphocyte
proliferation, inducing melanoma cell death.
Even if the role of SHP-2 in modulating antitumor activity of immune infiltrate needs to be
better investigated, reported results suggest that targeting SHP-2 in immune cells may be a promising
approach for melanoma treatment.
3.3. Tyrosine-Protein Phosphatase Non-Receptor Type 2 (PTPN2)
PTPN2, also known as T-cell protein tyrosine phosphatase (TC-PTP), is ubiquitously expressed and
has important functions [214] in modulating immune cell signaling [215], inflammatory responses [216],
hematopoietic stem cell renewal [217], insulin signaling [218], and leptin regulation [219]. Importantly,
several recent studies outlined a key role of PTPN2 in modulating oncogenic signaling. While few
papers attribute a tumor-suppressive function to PTPN2 [220–223], many studies support its oncogenic
role. For example, PTPN2 has been found to be overexpressed in B cell lymphomas, where its
upregulation is under the control of MYC [224]. In addition, PTPN2 promotes IGF-2 induced migration
in MCF-7 breast cancer cells [225].
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Using Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR associated protein 9
(CRISPR/Cas9) genome editing, Manguso and co-workers recently performed a pooled loss-of-function
genetic screening in mice tumors derived from transplantable B16 melanoma cells. Mice were treated
with immunotherapy in order to discover new potential targets involved in the resistance to this
approach. Interestingly, among the genes depleted in immunotherapy-treated mice, PTPN2 was one of
the most representative. Specifically, loss-of-function of PTPN2 sensitized B16 cells to immunotherapy
in vivo and increased the sensitivity to T cell immunity in a Braf/Pten melanoma model, without affecting
cell viability and growth in the absence of T cells. It is noteworthy that the re-expression of PTPN2
in PTPN2-null tumors abrogated the response to immunotherapy in vivo and the overexpression of
PTPN2 in B16 cells promoted immunotherapy resistance. Moreover, the composition of the immune
cell population in the tumor microenvironment was strongly altered in PTPN2-null tumors displaying
a higher number of activated and cytotoxic CD8+T cells and γδ+ T cells. In addition, loss of PTPN2
increased antigen presentation and sensitivity to CD8+T cells. In order to dissect the mechanism by
which PTPN2 acts as an oncogene in melanoma and how its loss correlates with increased sensitivity
of tumor cells to immunotherapy, it is important to underline that the tyrosine phosphatase inhibits
IFNγ signaling by dephosphorylating STAT1 and JAK1. Indeed, PTPN2 deletion in B16 tumor cells
enhanced IFNγ signaling, caused a strong change in the expression profile of IFNγ response gene,
and increased phosphorylation of STAT1, thereby reducing tumor growth of PTPN2-null mice [226].
Moreover, a very recent study disclosed a new role of PTPN2 as a key regulator of the differentiation
of the terminally exhausted CD8+T cell subpopulation by attenuating type I interferon signaling.
Indeed, PTPN2 loss in the immune system subpopulation, CD8+T cells, induces PD-1 checkpoint
blockade response to B16 tumors [227].
Despite no PTPN2 inhibitors having been extensively studied to date, the previously reported
promising results revealing the oncogenic role of PTPN2 strongly suggest the necessity to design
selective inhibitors of this phosphatase in order to potentiate the sensitivity of melanoma to the effects
of immunotherapy.
4. Discussion
The discovery that mutated or constitutively activated tyrosine kinases contribute to melanocyte
transformation pointed the attention to the importance of altered tyrosine phosphorylation in supporting
different aspects of melanoma progression. This evidence paved the way for the development of tyrosine
kinase inhibitors for the treatment of the unresectable form of melanoma [228]. Hence, many tyrosine
kinase inhibitors have been synthesized in the past decades, and quickly approved for the treatment of
patients affected by advanced metastatic melanoma. Although this therapeutic approach has produced
clear benefits [229], clinical data revealed that a significant percentage of patients expressing mutated
forms of oncogenic tyrosine kinases develop resistance to the treatment over the time, highlighting the
need to find alternative therapeutic approaches [230].
A possible solution to this issue has recently emerged from the modulation of the activity of PTPs.
Indeed, although many members of the PTP family behave as a tumor suppressor, several studies
underscored a key role for PTPs as tumor promoters in different types of cancer [8]. This scenario
suggested that the targeting of PTPs could be a promising alternative strategy to fight cancer
progression. Despite the difficulties arising from the fact that all PTPs share the same charged active
site, many advances have been made in the development of specific, cell-permeable, and bioavailable
PTP inhibitors, mainly allosteric ones [231]. The first study about the possibility of inhibiting PTPs
for melanoma treatment came from the late 1990s when Steinman and collaborators reported that
the administration of different PTPs inhibitors, such as sodium orthovanadate and phenylarsine
oxide, strongly inhibited melanoma metastasis formation, thus reducing tumor aggressiveness [232].
Preclinical studies subsequently revealed that some molecules targeting PTPs are able to slow down
proliferation and reduce the metastatic dissemination of many aggressive forms of cancers without
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producing side effects, suggesting the possibility of introducing these compounds in the therapy
against melanoma [21,231].
The evidence reported in this review confirms this hypothesis and shows that some of the
PTPs previously described to have oncogenic functions also play an important role in promoting
melanoma cell proliferation and survival [30–35]. In addition, some of these PTPs are implicated in
the inactivation of the immune response, contributing to immune surveillance evasion of melanoma
cells [195,196,209,226,227]. The relevance of PTPs in sustaining melanoma aggressiveness is further
confirmed by tests carried out on mice xenografted with melanoma cells, revealing that treatment with
PTPs inhibitors impairs proliferation, migration, and invasiveness of cancer cells [116,130], and enhances
the antitumoral immune response [154,205,206,226]. Interestingly, many of the PTP inhibitors proposed
above have been designed to overcome the highly conserved and positively charged nature of PTP
active sites, thus ensuring a good specificity for their targets. For example, the SHP-2 inhibitor 11a-1,
demonstrated to be effective against melanoma both in vitro and in vivo [163], has an IC50 over 5-fold
more selective for SHP2 than any other PTPs tested. This specificity is correlated to its bidentate
structure, which facilitates the access and the anchorage to both the SHP2 active site and a unique
peripheral binding site, increasing its selectivity and potency [163]. The step-by-step modification
strategy is also successful for the identification of new inhibitors. This approach, by optimizing the
previously proposed CDC25B inhibitor NSC28620, led Cerchia and co-workers to the identification of
the main structural requirements necessary to obtain the optimal inhibitory activity and specificity to
design selective inhibitors against CDC25B [83].
Moreover, it is important to notice that some PTPs are simultaneously overexpressed in both
cancer and immune cells, often displaying opposite functions. In these cases, it would be necessary to
have some caution before proposing them as a possible therapy, evaluating the possibility of targeting
the enzymes exclusively in one of the two populations.
For instance, it has been reported that LMW-PTP has a positive role in regulating the activation of
lymphocytes [233,234], while it also promotes resistance of melanoma cells toward cytotoxic drugs [31].
As a consequence, the treatment of patients affected by melanoma with LMW-PTP inhibitors could
induce a paradoxical effect, inhibiting on the one side, the proliferation of cancer cells, but on the other,
impairing the immune response.
Different is the case of SHP-2, which plays a key role in sustaining melanoma cell survival,
and behaves, at the same time, as a negative regulator of T lymphocytes [235]. Therefore, in this
case, treatment with SHP-2 inhibitors could generate a synergistic effect, dampening melanoma cell
growth [22] and at the same time potentiating the activation of immune cells [236].
In conclusion, in our opinion, future studies should be focused, on the one hand, on clarifying the
physiological roles of PTPs in order to predict the efficacy of new targeted therapies based on their
inhibition and, on the other, to synthesize more specific PTP inhibitors with a view to generating novel
potential antitumoral drugs.
5. Conclusions
In synthesis, information collected in this review demonstrates that PTPs represent interesting
molecules that can be targeted to fight the most aggressive forms of melanoma. PTP inhibitors could
be successfully used, alone or in combination, to arrest melanoma progression while also potentiating
antitumor immune surveillance. Based on the promising results obtained so far, PTP inhibitors could
be proposed as a potential adjuvant therapy for the treatment of melanoma.
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